Neuroprotective effect of humanin in an in vitro Parkinson’s disease model


Creative Commons License

Şengül G.

FENS Regional Meeting, Belgrade, Serbia And Montenegro, 10 July - 13 September 2019

  • Publication Type: Conference Paper / Unpublished
  • City: Belgrade
  • Country: Serbia And Montenegro

Abstract

Neuroprotective effect of humanin in an in vitro Parkinson’s disease model

Gulgun Sengul1,2, Seyhmus Bayar1, Seyma Tasdemir3,4, Buse Kayhan1, Aylin Sendemir3

1Department of Neuroscience, Institute of Health Sciences, Ege University, Izmir, Turkey

2Department of Anatomy, School of Medicine, Ege University, Izmir, Turkey

3Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey

4Department of Bioengineering, Faculty of Engineering and Architecture, Sinop University, Sinop, Turkey

Abstract                                                                       

Aims: Humanin (HN), a peptide with 24 amino acids, has been studied in many neurodegenerative diseases including Alzheimer's disease after its discovery. The aim of this study was to investigate whether HN has a neuroprotective effect in an in vitro Parkinson's disease model induced by 6-hydroxydopamine (6-OHDA).

Methods: SH-SY5Y human neuroblastoma cell line was used to model Parkinson's disease in vitro. The neuroprotective effect of HN against 6-OHDA neurotoxicity was investigated through mitochondrial dysfunction, apoptosis and cytotoxicity parameters. Different concentrations of 6-OHDA (1600-100 µM) and HN (20-0.3125 µM) were applied on cells. The neuroprotective effect of HN was investigated using MTT, LDH and caspase-3 assays. Statistical analysis was performed using GraphPad Prism 8 program. The differences between the groups were evaluated with one-way ANOVA statistics.

Results: The IC50 dose was calculated as 233.7 µM. HN did not have a proliferative effect when administered alone. However, 24 h pretreatment by 10 µM and 20 µM HN showed a neuroprotective effect against 6-OHDA neurotoxicity (p<0.01). LDH secretion was not detected in any HN dose group. HN decreased caspase-3 levels but this difference was not statistically significant (p>0.05).

Conclusion:  The results of this study show a HN has a neuroprotective effect of HN against 6-OHDA neurotoxicity. This should be further investigated in other in vitro and in vivo animal Parkinson's disease models to reveal if it can be used in the treatment of Parkinson's disease.

Keywords: apoptosis, cytotoxicity, humanin, neuroprotection, mitochondrial dysfunction, Parkinson’s disease

 

Acknowledgements: This study was supported by the Ege University Scientific Research Fund (Project number: 18-SBE-005).

Neuroprotective effect of humanin in an in vitro Parkinson’s disease model

Gulgun Sengul1,2, Seyhmus Bayar1, Seyma Tasdemir3,4, Buse Kayhan1, Aylin Sendemir3

1Department of Neuroscience, Institute of Health Sciences, Ege University, Izmir, Turkey

2Department of Anatomy, School of Medicine, Ege University, Izmir, Turkey

3Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey

4Department of Bioengineering, Faculty of Engineering and Architecture, Sinop University, Sinop, Turkey

Abstract                                                                       

Aims: Humanin (HN), a peptide with 24 amino acids, has been studied in many neurodegenerative diseases including Alzheimer's disease after its discovery. The aim of this study was to investigate whether HN has a neuroprotective effect in an in vitro Parkinson's disease model induced by 6-hydroxydopamine (6-OHDA).

Methods: SH-SY5Y human neuroblastoma cell line was used to model Parkinson's disease in vitro. The neuroprotective effect of HN against 6-OHDA neurotoxicity was investigated through mitochondrial dysfunction, apoptosis and cytotoxicity parameters. Different concentrations of 6-OHDA (1600-100 µM) and HN (20-0.3125 µM) were applied on cells. The neuroprotective effect of HN was investigated using MTT, LDH and caspase-3 assays. Statistical analysis was performed using GraphPad Prism 8 program. The differences between the groups were evaluated with one-way ANOVA statistics.

Results: The IC50 dose was calculated as 233.7 µM. HN did not have a proliferative effect when administered alone. However, 24 h pretreatment by 10 µM and 20 µM HN showed a neuroprotective effect against 6-OHDA neurotoxicity (p<0.01). LDH secretion was not detected in any HN dose group. HN decreased caspase-3 levels but this difference was not statistically significant (p>0.05).

Conclusion:  The results of this study show a HN has a neuroprotective effect of HN against 6-OHDA neurotoxicity. This should be further investigated in other in vitro and in vivo animal Parkinson's disease models to reveal if it can be used in the treatment of Parkinson's disease.

Keywords: apoptosis, cytotoxicity, humanin, neuroprotection, mitochondrial dysfunction, Parkinson’s disease

 

Acknowledgements: This study was supported by the Ege University Scientific Research Fund (Project number: 18-SBE-005).